First-line immunotherapy outperforms chemotherapy in MSI-H/dMMR metastatic colorectal cancer

◆ TRIAL DATA

A meta-analysis of phase III trials confirms immune checkpoint inhibitors show superior progression-free and overall survival compared to standard chemotherapy as first-line treatment for patients with MSI-H or dMMR metastatic disease. (J Gastrointest Cancer)